145 related articles for article (PubMed ID: 15460522)
21. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
[TBL] [Abstract][Full Text] [Related]
22. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H
Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886
[TBL] [Abstract][Full Text] [Related]
23. Impact of HIV-1 pol diversity on drug resistance and its clinical implications.
Kantor R
Curr Opin Infect Dis; 2006 Dec; 19(6):594-606. PubMed ID: 17075337
[TBL] [Abstract][Full Text] [Related]
24. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
25. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Prado JG; Parkin NT; Clotet B; Ruiz L; Martinez-Picado J
Clin Infect Dis; 2005 Sep; 41(5):729-37. PubMed ID: 16080097
[TBL] [Abstract][Full Text] [Related]
26. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
27. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 drug resistance in variants from the female genital tract and plasma.
Kemal KS; Burger H; Mayers D; Anastos K; Foley B; Kitchen C; Huggins P; Schroeder T; Picchio G; Back S; Gao W; Meyer WA; Weiser B
J Infect Dis; 2007 Feb; 195(4):535-45. PubMed ID: 17230413
[TBL] [Abstract][Full Text] [Related]
29. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
[TBL] [Abstract][Full Text] [Related]
30. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
Wensing AM; van de Vijver DA; Angarano G; Asjö B; Balotta C; Boeri E; Camacho R; Chaix ML; Costagliola D; De Luca A; Derdelinckx I; Grossman Z; Hamouda O; Hatzakis A; Hemmer R; Hoepelman A; Horban A; Korn K; Kücherer C; Leitner T; Loveday C; MacRae E; Maljkovic I; de Mendoza C; Meyer L; Nielsen C; Op de Coul EL; Ormaasen V; Paraskevis D; Perrin L; Puchhammer-Stöckl E; Ruiz L; Salminen M; Schmit JC; Schneider F; Schuurman R; Soriano V; Stanczak G; Stanojevic M; Vandamme AM; Van Laethem K; Violin M; Wilbe K; Yerly S; Zazzi M; Boucher CA;
J Infect Dis; 2005 Sep; 192(6):958-66. PubMed ID: 16107947
[TBL] [Abstract][Full Text] [Related]
32. Drug resistance testing in PBMCs of HIV infected patients.
Tagliaferro L; Menegazzi P; Cataldini S; De Simone M; Chiriacò P; Varnier OE
New Microbiol; 2001 Oct; 24(4):325-32. PubMed ID: 11718369
[TBL] [Abstract][Full Text] [Related]
33. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
Hance AJ; Lemiale V; Izopet J; Lecossier D; Joly V; Massip P; Mammano F; Descamps D; Brun-Vézinet F; Clavel F
J Virol; 2001 Jul; 75(14):6410-7. PubMed ID: 11413308
[TBL] [Abstract][Full Text] [Related]
34. Evidence for positive epistasis in HIV-1.
Bonhoeffer S; Chappey C; Parkin NT; Whitcomb JM; Petropoulos CJ
Science; 2004 Nov; 306(5701):1547-50. PubMed ID: 15567861
[TBL] [Abstract][Full Text] [Related]
35. Methods to determine HIV-1 ex vivo fitness.
Abraha A; Troyer RM; Quiñones-Mateu ME; Arts EJ
Methods Mol Biol; 2005; 304():355-68. PubMed ID: 16061989
[TBL] [Abstract][Full Text] [Related]
36. New viral fitness test helps determine regimens.
AIDS Alert; 2002 Aug; 17(8):100-1. PubMed ID: 12647689
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and primary evaluation of novel HIV-1 inhibitors.
El Safadi Y; Marquet R; Aubertin AM; Vivet-Boudou V
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1161-5. PubMed ID: 18058557
[TBL] [Abstract][Full Text] [Related]
39. Estimating HIV-1 fitness characteristics from cross-sectional genotype data.
Gopalakrishnan S; Montazeri H; Menz S; Beerenwinkel N; Huisinga W
PLoS Comput Biol; 2014 Nov; 10(11):e1003886. PubMed ID: 25375675
[TBL] [Abstract][Full Text] [Related]
40. Fitness of drug resistant HIV-1: methodology and clinical implications.
Quiñones-Mateu ME; Arts EJ
Drug Resist Updat; 2002 Dec; 5(6):224-33. PubMed ID: 12531179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
